<DOC>
	<DOCNO>NCT01398293</DOCNO>
	<brief_summary>This single-dose , randomize , double-blind , double-dummy , placebo-controlled , positive-controlled four-way crossover study evaluate effect single dose danoprevir low-dose ritonavir QC/QTc interval healthy volunteer . Subjects randomly assign one four sequence treatments A : therapeutic dose danoprevir plus ritonavir ( DNV/r ) , B : supratherapeutic dose DNV/r , C : moxifloxacin D : placebo , washout period least 7 day treatment .</brief_summary>
	<brief_title>A Study Danoprevir Combination With Low-Dose Ritonavir Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Adult healthy volunteer , 18 60 year age Female subject must surgically sterile postmenopausal Male subject partner childbearing potential must use method contraception duration study three month last drug administration Agree abstain strenuous exercise three day dose throughout study ( include washout period followup visit ) History evidence clinically significant disease disorder Pregnant lactate woman Male partner woman lactate try become pregnant Current smoker subject discontinue smoke less six month prior first dose Positive alcohol breath test ; suspicion regular consumption drug abuse Positive hepatitis B , hepatitis C HIV infection Participation investigational drug , biologic , device study within three month first study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>